Lyra Therapeutics (LYRA) Expected to Announce Earnings on Thursday

Lyra Therapeutics (NASDAQ:LYRA) is expected to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($1.24) per share and revenue of $0.44 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 4:00 PM ET.

Lyra Therapeutics Price Performance

LYRA opened at $1.30 on Wednesday. The company’s 50 day moving average price is $1.92 and its two-hundred day moving average price is $4.22. The firm has a market capitalization of $2.30 million and a price-to-earnings ratio of -0.06. Lyra Therapeutics has a fifty-two week low of $0.91 and a fifty-two week high of $37.50.

Hedge Funds Weigh In On Lyra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its stake in Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Lyra Therapeutics during the 3rd quarter worth approximately $128,000. Finally, DRW Securities LLC purchased a new position in Lyra Therapeutics in the fourth quarter valued at approximately $52,000. 95.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lyra Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Lyra Therapeutics has a consensus rating of “Reduce” and an average target price of $100.00.

Lyra Therapeutics Company Profile

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).